1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Wakix |
| structure | File | |
| classes | List of String, delimiter: , | Histamine H3 receptor inverse agonist / antagonist • wake-promoting agent |
| mechanism | String | |
| uses | String | Excessive daytime sleepiness or cataplexy in adults with narcolepsy (FDA-approved August 2019) |
| starting_dose | String | Week 1: 8.9 mg PO once daily in the morning. Week 2: 17.8 mg. Week 3+: 35.6 mg (max). Titrate as needed. |
| preparations | String | 4.45 mg, 17.8 mg tablets |
| fda_max | String | 35.6 mg/d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Wake-promoting effect over weeks of titration |
| duration | String | Daily morning dosing |
| halflife | String | ~20 hours |
| bioavailability | String | Not formally established; oral once-daily adequate |
| pregnancy | String | Limited data; pitolisant may reduce hormonal contraceptive efficacy |
| legal | String | Rx, '''not a controlled substance''' (unique among wake-promoting agents) |
